Ignite Creation Date:
2024-05-06 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06195085
Status:
COMPLETED
Last Update Posted:
2024-01-08
First Post:
2023-12-22
Brief Title:
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Sponsor:
Peking University Third Hospital
Organization:
Peking University Third Hospital
Study Overview
Official Title:
Long-term Outcomes of CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 I-125 seed implantation RISI for recurrent desmoid tumor
A multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving RISI from July 2013 to July 2021The clinical outcomes including overall response rate ORR disease control rate DCR local control time LCT overall survival OS adverse events AEs and symptom relief rate were statistically assessed
A multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving RISI from July 2013 to July 2021The clinical outcomes including overall response rate ORR disease control rate DCR local control time LCT overall survival OS adverse events AEs and symptom relief rate were statistically assessed
Detailed Description:
Desmoid tumor was characterized by a high potential of recurrence even following initial definitive treatment There were considerable controversies regarding the management of recurrent desmoid tumor This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 I-125 seed implantation RISI for recurrent desmoid tumor
38 patients diagnosed with recurrent desmoid tumor undergoing RISI in 3 different centers including Peking University Third Hospital First Affiliated Hospital of the Army Medical University and Shengli Oilfield Central Hospital from July 2013 to July 2021 were reviewed consecutively
The clinical outcomes including overall response rate ORR disease control rate DCR local control time LCT overall survival OS adverse events AEs and symptom relief rate were statistically assessed
38 patients diagnosed with recurrent desmoid tumor undergoing RISI in 3 different centers including Peking University Third Hospital First Affiliated Hospital of the Army Medical University and Shengli Oilfield Central Hospital from July 2013 to July 2021 were reviewed consecutively
The clinical outcomes including overall response rate ORR disease control rate DCR local control time LCT overall survival OS adverse events AEs and symptom relief rate were statistically assessed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None